- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Pulmonary fibrosis drug developer Avalyn files IPO | ||
| Do | NHS risks missing out on independent prescriber benefits | ||
| Do | AbbVie tries a new approach in 340B programme battle | ||
| Do | 23andMe study explains variable results with obesity drugs | ||
| Do | Syneron raises $150m for macrocyclics, and other financings | ||
| Do | Syneron raises $150m for macrocylics, and other financings | ||
| Mi | Activist investor renews its criticism of Novavax | ||
| Mi | Jeito closes 'record' $1.2bn Europe-focused biopharma fund | ||
| Mi | EU invests €30m to fight antimicrobial resistance | ||
| Mi | US judge blocks bid to curb abortion pill access | ||
| Di | Gilead strikes again, penning $5bn deal to buy Tubulis | ||
| Di | Kennedy changes vaccine panel charter after legal setback | ||
| Di | AI giant Anthropic buys Coefficient Bio for $400m | ||
| Di | Sanofi's bispecific lunsekimig has mixed readouts in phase 2 | ||
| Di | Amgen scores with new thyroid eye disease formulation | ||
| Di | Neurocrine pays $2.9bn for Soleno and extreme hunger drug | ||
| 03.04. | US pharma tariffs of up to 100% finalised by Trump | ||
| 02.04. | Ambrosia's sweet $100m round, and other biofinancings | ||
| 02.04. | Immunovant's thyroid eye disease drug flunks pivotal trials | ||
| 02.04. | AZ claims another win for Imfinzi in frontline liver cancer | ||
| 02.04. | Threat of Trump's pharma tariffs looms again | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | ||
| 01.04. | Lilly bags FDA okay for Wegovy pill rival orforglipron | ||
| 01.04. | DNA testing can help right racial imbalance in breast cancer | ||
| 01.04. | EMA seeks input on virtual alternative to animal test |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.